To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three times daily or matching placebo three times daily for 5 days and who are followed for a total of 13 days.

Current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir

Prior hypersensitivity &/or allergic reaction to acyclovir

Use of probenicid

Current use, or use within past 28 days, of an investigational agent

Currently pregnant or nursing

Currently plan to become pregnant during next 3 months

Any condition that will interfere with successful completion of study procedures

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00808405